Almac SA

#back-to-top { display: block; position: fixed; bottom: 0.75rem; left: 0.75rem; z-index: 9999; width: 100%; height: 40px; text-align: center; line-height: 40px; background: #000; color: #fff; cursor: pointer; border: 0; border-radius: 2px; text-decoration: none; transition: opacity 0.2s ease-out; opacity: 0; } #back-to-top:hover { background: #333; } #back-to-top.show { opacity: 1; } @media only screen and (min-width: 40rem) { #back-to-top { background: #d62828; height: 40px; line-height: 40px; bottom: 0.75rem; left: 0.75rem; width: 40px; } } @media only screen and (min-width: 70rem) { #back-to-top { height: 50px; line-height: 50px; bottom: 1rem; left: 1rem; width: 50px; } } .timeline .figure_content { padding-top: 1rem; } .timeline h2 { font-size: 1.625rem; font-weight: 800; margin: 0 0 1rem 0; } .timeline h2 a { text-decoration: none; } .timeline h2 a:hover { text-decoration: underline; } /* Updated CSS for timeline list */ .timeline ol { -webkit-columns: 1; -moz-columns: 1; columns: 1; list-style: none; margin: 1rem 0 0 0; padding: 0; /* Removes default padding */ position: relative; } .timeline ol li { display: flex; align-items: center; font-weight: 700; margin: 0 0 0.75rem 1rem; /* Adjust spacing */ position: relative; } .timeline ol li .list-date { flex-shrink: 0; font-size: 0.875rem; font-weight: 400; padding-right: 0.5rem; width: 60px; /* Adjust as needed */ text-align: center; /* Centers the text */ } .timeline ol li a { font-size: 1rem; font-weight: 700; text-decoration: none; } .timeline ol li a:hover { text-decoration: underline; } .timeline ol li:before { background-color: #000; border-radius: 50%; content: ““; height: 10px; left: -20px; position: absolute; top: 5px; width: 10px; } .timeline ol li:after { position: absolute; content: ''; display: inline-block; background-color: #000; width: 2px; left: -16px; top: 15px; height: 110%; } .timeline ol li:last-of-type:after { display: none; } .timeline .brief-item { margin-top: 3rem; position: relative; } .timeline .brief-item:last-of-type:after { height: 100%; } .timeline .brief-item .brief-item-img { margin: 0.5rem 0 0 0; } .timeline .brief-item .details { margin: 0; } .timeline .brief-item .image-cite { color: #999; font-size: 0.875rem; } .timeline .brief-item .image-cite .credit { font-style: italic; } .timeline .brief-item .image-cite .credit a { color: #999; } .timeline .brief-item .date-tag { background-color: #000; color: #fff; display: inline-block; font-weight: 800; font-size: 0.875rem; line-height: 20px; margin: 0.25rem 0; padding: 0.25rem 0.5rem; } .timeline .last-updated { color: #d62828; font-style: normal; font-size: 1rem; font-weight: 700; } .timeline .learn-more { font-style: italic; margin-top: 2rem; font-size: 1rem; } @media only screen and (min-width: 40rem) { /* Single-column layout for larger screens */ .timeline ol { -webkit-columns: 1; -moz-columns: 1; columns: 1; } .timeline ol li { margin-left: 0; } .timeline ol li:before, .timeline ol li:after { display: none; } .timeline h2 { font-size: 2rem; margin: 0 0 1rem 0; } .timeline .brief-item .brief-item-img { margin: 1.5rem 0 0 0; } .speaker-headshot { border-radius: 50%; /* width: 100px; height: 100px; */ width: 8vw; max-width: 100px; object-fit: cover; } .timeline .brief-item:before { background-color: #000; border-radius: 50%; content: ““; height: 15px; left: -40px; position: absolute; top: 5px; width: 15px; } .timeline .brief-item:after { position: absolute; content: ''; display: inline-block; background-color: #000; width: 2px; left: -33px; top: 15px; height: 102%; } .timeline .brief-item .date-tag { margin: 0 0 1rem 0; } .timeline .brief-item .date-tag:before { content: ““; position: absolute; left: -14px; top: 0; width: 0; height: 0; border-top: 14px solid transparent; border-bottom: 14px solid transparent; border-right: 14px solid #000; } } Emerging biopharma companies are now taking the lead on drug development, with smaller and more agile firms able to meet aggressive timelines and navigate unique logistical and regulatory challenges. From business development to clinical supply management, various project management duties play a vital role in the execution of clinical trials. This three-part podcast series provides insights and guidance about how emerging biopharma companies can successfully run complex clinical trials and deliver patient-benefitting drugs and treatments. Check out the podcast episode below! r Ep. 3r Mastering Clinical Supply: How Clinical Supply Managers Turn Challenges into Solutionsr --> r Ep. 2r Planning for Success: Embracing Strategic Solutions to Boost Flexibility, Reduce Waste, and Empower Patient-Centric Clinical Trialsr --> Ep. 1 From Concept to Delivery: Navigating the Challenges of Clinical Trial Set-Up and Maintenance To Optimize Performance r Ep. 3r Mastering Clinical Supply: How Clinical Supply Managers Turn Challenges into Solutionsr As the clients advocate, the clinical supply manager (CSM) navigates the complexities of supply management, from drug receipt to final disposition, ensuring trials stay on track despite evolving challenges. In episode 3 of our three-part podcast series, dive into the vital role of CSMs in the execution of clinical trials.r r r r r Listen to “Mastering Clinical Supply: How Clinical Supply Managers Turn Challenges into Solutions“ on Spreaker.r r r r r --> r Ep. 2 r Planning for Success: Embracing Strategic Solutions to Boost Flexibility, Reduce Waste, and Empower Patient-Centric Clinical Trialsr Once study requirements are complete, emerging biopharma companies must tackle unique project management challenges. Varying, complex regulatory timelines and differing drug shipment requirements by country complicate the process. Discover strategic solutions to bring trials in on time and on budget in episode 2 of our three-part podcast series.r r r r r Listen to “Planning for Success: Embracing Strategic Solutions to Boost Flexibility, Reduce Waste, and Empower Patient-Centric Clinical Trials“ on Spreaker.r r r r r --> Ep. 1 From Concept to Delivery: Navigating the Challenges of Clinical Trial Set-Up and Maintenance To Optimize Performance In a fiercely competitive drug development landscape, traditional large-scale players are falling behind smaller and more agile firms. Emerging biopharma companies now need a lot of support and education to meet aggressive timelines. Learn how to navigate the challenges of clinical trial set-up and maintenance. Listen to “From Concept to Delivery: Navigating the Challenges of Clinical Trial Set-up and Maintenance to Optimize Performance“ on Spreaker. //smooth scroll $(function() { $('a[href*=“#“]:not([href=“#“])').click(function() { if (location.pathname.replace(/^//,'') == this.pathname.replace(/^//,'') && location.hostname == this.hostname) { var target = $(this.hash); target = target.length ? target : $('[name=' + this.hash.slice(1) +']'); if (target.length) { $('html, body').animate({ scrollTop: (target.offset().top - 100) }, 1000); return false; } } }); }); if ($('#back-to-top').length) { var scrollTrigger = 1400, // px backToTop = function () { var scrollTop = $(window).scrollTop(); if (scrollTop > scrollTrigger) { $('#back-to-top').addClass('show'); } else { $('#back-to-top').removeClass('show'); } }; backToTop(); $(window).on('scroll', function () { backToTop(); });} '

The CDMO saw a revenue rise over the second year of its global expansion kick. While several CDMO giants have been weathering an industry slowdown in recent years following the pandemic and longing for better days, Almac Group is busy enjoying a growth spurt. Over a busy year ending on Sept. 30, revenue at the U.K.-based manufacturer rose 14% from last year to 958 million pounds ($1.2 billion). The revenue uptick comes during a major global expansion that was announced in 2021 to the tune of 400 million pounds ($508 million). Just this year, Almac wrapped up work on two new facilities in Craigavon, Northern Ireland. One of the plants makes and packages sachet drug products and the other will more than double the company’s peptide API manufacturing capacity. So far, the expansion drive has created 1,800 new jobs, swelling Almac’s total headcount to more than 7,300. During the financial year, the CDMO helped to develop “hundreds of life-saving drugs spanning more than 20 therapeutic areas,” according to a release Tuesday. Recent products Almac has helped supply include Agios’ rare blood disease therapy Pyrukynd, Sanofi’s diabetes injection Tzield and PTC’s brain-infused gene therapy Upstaza, to name a few. Almac’s revenue growth is somewhat of an outlier in the wider CDMO landscape. Manufacturers such as Catalent, Lonza and AGC Biologics face sliding sales amid lagging funding compared to the pandemic boom. AGC Biologics, for example, laid off just under 4% of its global workforce earlier this month due to “changing economies” and “other external factors” that led the Seattle-based CDMO to decide to “right size and rebalance the resources of our organization,” a spokesperson said at the time. During a recent Evaluate webinar on the state of the manufacturing industry in 2024, CDMO sales lead for Pfizer CenterOne’s North America sector pointed out that much of the funding following a pandemic surge of venture capital interest in small- and mid-sized biotechs has dried up, leaving many CDMOs with fewer contracts. Some, like Lonza, are looking on the bright side. The manufacturer recently flagged “initial signs” of an industry recovery for early-stage work. The Swiss company just inked a $1.2 billion deal to purchase a large biologics facility in California from Roche’s Genentech.

To meet growing demand for its services, Northern Ireland CDMO Almac has completed the construction of two new facilities. One will more than double its capacity to produce peptides. In its continuing expansion blitz, Almac has completed new two facilities at its headquarters in Craigavon, Northern Ireland, which will expand the capacity of the CDMO to package commercial products and to manufacture peptides. In one expansion project, the 55-year-old private company has finished a 32,000-square-foot facility that increases its ability to manufacture and package sachet drug products, Almac said in a Wednesday release. The site features large-scale manufacturing suites and quality control lab testing.   Sachet drugs are precisely packaged to enable accurate dosing while allowing portability. Almac also has built a 28,000-square-foot facility that will more than double its peptide API manufacturing capacity to meet the growing demand for clinical development and commercial products.  “Our new peptide API manufacturing facility will significantly grow our portfolio of client APIs and is the latest stage of a wider development and manufacturing expansion initiative for Almac Sciences,” Graeme McBurney, Almac’s chief operating officer, said in a release. In 2022, the company announced an investment of 200 million pounds ($247 million) to “meet increased client demand” worldwide over the next three years. Then, five months ago, the company declared that 80 million pounds ($102 million) was designated to add 140,000 square feet at headquarters and house an additional 550 employees. The company's head count totals more than 7,000. Almac also is growing its presence in the U.S. In 2022, the company pegged $93.5 million for expansion of its North American headquarters in Souderton, Pennsylvania. The expansion is adding 100,000 square feet to the 246,000-square-foot facility, paving the way for the addition of 355 new staffers. Among the products Almac has helped launch over the last two years are Agios’ Pyrukynd, Sanofi's Tzield and PTC’s gene therapy Upstaza. The company also has a partnership with AstraZeneca.